HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
Archiv der Pharmazie · 2026
DOI: 10.1002/ardp.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2026. Verfasst von Mohammad Hassan Baig und 12 weiteren Autor:innen. Beteiligte Einrichtung: BNJ Biopharma, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Korea Technology and Information Promotion Agency for SMEs, Korea Institute for Advancement of Technology, Korea Institute of Startup & Entrepreneurship Development.
Abstract (Originalsprache)
The emergence of the EGFR C797S mutation poses a significant challenge in the treatment of non‐small cell lung cancer due to resistance to third‐generation EGFR‐tyrosine kinase inhibitors. This study introduces a novel and highly selective EGFR PROTAC, HBE‐843, designed to degrade mutant EGFR while sparing wild‐type EGFR. Our degrader not only effectively degrades the L858R but also shows promising activity against exon 19 deletion, T790M, and C797S, where it demonstrated low nanomolar GI 50 (26–103 nM) across all these EGFR mutant‐harboring cell lines while sparing the wild‐type. HBE‐843 effectively reduced EGFR protein levels in mutant cells in a dose‐dependent manner, with a DC 50 in the low nanomolar range (1.9–18 nM) and a D max above 90%. Mechanistic studies showed that HBE‐843 mediates EGFR degradation through the CRBN‐associated proteasome pathway, preventing the activation of the ERK downstream signal and hindering cell growth. In vivo studies demonstrated a 112% tumor growth inhibition in L858R‐induced cancers. These findings suggest that HBE‐843 holds promise as a lead compound for developing new drugs to overcome C797S mutant‐mediated resistance in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- BNJ Biopharma, Incheon, Republic of Korea.
- Handok Inc., Seoul, Republic of Korea.
- Department of Family Medicine, Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Republic of Korea.
- Graduate School of Future Strategy, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Graduate School of Future Strategy and Data Science, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
ORCID-Profile: Mohammad Hassan Baig, Chang Joong Kim, Sang-Heon Kim, Sungwook Ryu
Förderung
- Korea Technology and Information Promotion Agency for SMEs
- Korea Institute for Advancement of Technology
- Korea Institute of Startup & Entrepreneurship Development
Zitieren
APA
Baig, M. H., Kim, C. J., Dattatraya, N. S., Seong, J. Y., Bok, J., Kim, H., Park, J., Choi, M., Kim, S. H., Moon, B., Dong, J., Yi, S., & Ryu, S. (2026). HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70193
Vancouver
Baig MH, Kim CJ, Dattatraya NS, Seong JY, Bok J, Kim H, et al. HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer. Archiv der Pharmazie. 2026. doi:10.1002/ardp.70193
BibTeX
@article{Baig2026,
author = {Baig, Mohammad Hassan and Kim, Chang Joong and Dattatraya, Nale Sagar and Seong, Jo Yun and Bok, Juhan and Kim, Hyemi and Park, JiMin and Choi, Munkyung and Kim, Sang-Heon and Moon, ByoungGon and Dong, Jaejune and Yi, Sangyoon and Ryu, Sungwook},
title = {HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer},
journal = {Archiv der Pharmazie},
year = {2026},
doi = {10.1002/ardp.70193}
}
EUVIMED